Manmohan Singh, Ph.D. is a well-known expert in the area of vaccine formulations and adjuvant research and has been working in vaccine R&D for the last 20 years. He has authored over 120 peer reviewed manuscripts, review articles and book chapters in this area. Dr. Singh is on the editorial board of 9 International Journals . He is also the editor of several books on vaccine delivery systems and adjuvants. He is currently working as the Head of Global Drug Product Development at Novartis Vaccines in Holly Springs, NC, U.S.A. Maya Salnikova, Ph.D. is a well-known expert in the area of biologics, biosimilars and vaccine formulations. She has been working on development of novel formulations for the past 10 years in academia and industry. She has authored over 20 peer reviewed articles and book chapters. Dr. Salnikova is on the board of reviewers for Journal of Pharmaceutical Sciences and has contributed in organizing of international conferences. She is currently working as Drug Product Development Lead at Novartis Vaccines in Holly Springs, NC, U.S.A.

• Section I: NOVEL THERAPEUTIC APPROACHES1. Clinical Considerations in the Design, Evaluation and Development of Novel Therapies2. New Era in Gene Therapy3. Advances in Nanotechnology-Based Drug Delivery Platforms and Novel Drug Delivery Systems4. Novel Approaches for the Delivery of Biologics to the Central Nervous System5. Trends in Nonparenteral Delivery of Biologics, Vaccines and Cancer TherapiesSection II: NOVEL APPROACHES FOR BIOLOGICS6. Novel Generation of Antibody-Based Therapeutics7. Novel Approaches in Discovery and Design of Antibody-Based Therapeutics8. Novel Therapeutic Proteins and Peptides9. Biobetter BiologicsSection III: NOVEL APPROACHES FOR VACCINES10. Vaccines Against Non-Infectious, Non-Cancer Novel Targets11. Winning a Race Against Evolving Pathogens with Novel Platforms and Universal Vaccines12. Prime-Boost Vaccination: Impact on the HIV Vaccine FieldSection IV: NOVEL APPROACHES FOR CANCER THERAPIESIV.I Novel Therapeutic Approaches and Targets for Cancer13. Personalized Therapies for Cancer Treatment14. Hunting Molecular Targets for Anticancer Reagents by Chemical ProteomicsIV.II Novel Immunotherapies for Cancer15. Cancer Vaccines16. T-Cell Immunotherapy for Cancer17. Immunostimulators and Immunomodulators in Cancer TreatmentIV.III Novel Approaches for Cancer Therapy with Small Molecules18. Long-Circulating Therapies for Cancer Treatment19. Recent Advances and Trends in the Brain Delivery of Small Molecule Based Cancer Therapies

Manmohan Singh, Ph.D. is a well-known expert in the area of vaccine formulations and adjuvant research and has been working in vaccine R&D for the last 20 years. He has authored over 120 peer reviewed manuscripts, review articles and book chapters in this area. Dr. Singh is on the editorial board of 9 International Journals . He is also the editor of several books on vaccine delivery systems and adjuvants. He is currently working as the Head of Global Drug Product Development at Novartis Vaccines in Holly Springs, NC, U.S.A. Maya Salnikova, Ph.D. is a well-known expert in the area of biologics, biosimilars and vaccine formulations. She has been working on development of novel formulations for the past 10 years in academia and industry. She has authored over 20 peer reviewed articles and book chapters. Dr. Salnikova is on the board of reviewers for Journal of Pharmaceutical Sciences and has contributed in organizing of international conferences. She is currently working as Drug Product Development Lead at Novartis Vaccines in Holly Springs, NC, U.S.A.

• Section I: NOVEL THERAPEUTIC APPROACHES1. Clinical Considerations in the Design, Evaluation and Development of Novel Therapies2. New Era in Gene Therapy3. Advances in Nanotechnology-Based Drug Delivery Platforms and Novel Drug Delivery Systems4. Novel Approaches for the Delivery of Biologics to the Central Nervous System5. Trends in Nonparenteral Delivery of Biologics, Vaccines and Cancer TherapiesSection II: NOVEL APPROACHES FOR BIOLOGICS6. Novel Generation of Antibody-Based Therapeutics7. Novel Approaches in Discovery and Design of Antibody-Based Therapeutics8. Novel Therapeutic Proteins and Peptides9. Biobetter BiologicsSection III: NOVEL APPROACHES FOR VACCINES10. Vaccines Against Non-Infectious, Non-Cancer Novel Targets11. Winning a Race Against Evolving Pathogens with Novel Platforms and Universal Vaccines12. Prime-Boost Vaccination: Impact on the HIV Vaccine FieldSection IV: NOVEL APPROACHES FOR CANCER THERAPIESIV.I Novel Therapeutic Approaches and Targets for Cancer13. Personalized Therapies for Cancer Treatment14. Hunting Molecular Targets for Anticancer Reagents by Chemical ProteomicsIV.II Novel Immunotherapies for Cancer15. Cancer Vaccines16. T-Cell Immunotherapy for Cancer17. Immunostimulators and Immunomodulators in Cancer TreatmentIV.III Novel Approaches for Cancer Therapy with Small Molecules18. Long-Circulating Therapies for Cancer Treatment19. Recent Advances and Trends in the Brain Delivery of Small Molecule Based Cancer Therapies

Manmohan Singh, Ph.D. is a well-known expert in the area of vaccine formulations and adjuvant research and has been working in vaccine R&D for the last 20 years. He has authored over 120 peer reviewed manuscripts, review articles and book chapters in this area. Dr. Singh is on the editorial board of 9 International Journals . He is also the editor of several books on vaccine delivery systems and adjuvants. He is currently working as the Head of Global Drug Product Development at Novartis Vaccines in Holly Springs, NC, U.S.A. Maya Salnikova, Ph.D. is a well-known expert in the area of biologics, biosimilars and vaccine formulations. She has been working on development of novel formulations for the past 10 years in academia and industry. She has authored over 20 peer reviewed articles and book chapters. Dr. Salnikova is on the board of reviewers for Journal of Pharmaceutical Sciences and has contributed in organizing of international conferences. She is currently working as Drug Product Development Lead at Novartis Vaccines in Holly Springs, NC, U.S.A.

• Section I: NOVEL THERAPEUTIC APPROACHES1. Clinical Considerations in the Design, Evaluation and Development of Novel Therapies2. New Era in Gene Therapy3. Advances in Nanotechnology-Based Drug Delivery Platforms and Novel Drug Delivery Systems4. Novel Approaches for the Delivery of Biologics to the Central Nervous System5. Trends in Nonparenteral Delivery of Biologics, Vaccines and Cancer TherapiesSection II: NOVEL APPROACHES FOR BIOLOGICS6. Novel Generation of Antibody-Based Therapeutics7. Novel Approaches in Discovery and Design of Antibody-Based Therapeutics8. Novel Therapeutic Proteins and Peptides9. Biobetter BiologicsSection III: NOVEL APPROACHES FOR VACCINES10. Vaccines Against Non-Infectious, Non-Cancer Novel Targets11. Winning a Race Against Evolving Pathogens with Novel Platforms and Universal Vaccines12. Prime-Boost Vaccination: Impact on the HIV Vaccine FieldSection IV: NOVEL APPROACHES FOR CANCER THERAPIESIV.I Novel Therapeutic Approaches and Targets for Cancer13. Personalized Therapies for Cancer Treatment14. Hunting Molecular Targets for Anticancer Reagents by Chemical ProteomicsIV.II Novel Immunotherapies for Cancer15. Cancer Vaccines16. T-Cell Immunotherapy for Cancer17. Immunostimulators and Immunomodulators in Cancer TreatmentIV.III Novel Approaches for Cancer Therapy with Small Molecules18. Long-Circulating Therapies for Cancer Treatment19. Recent Advances and Trends in the Brain Delivery of Small Molecule Based Cancer Therapies